NewAmsterdam Pharma Reports 81% Revenue Decline and $64.1 Million Net Loss in Q2 2026

NewAmsterdam Pharma Company N.V. reported a significant decline in its financial performance for the second quarter of 2026, with revenues of $3.7 million, down 81% from $19.1 million in the same period last year. The decrease is attributed primarily to the absence of a $16.1 million revenue recognition from the Menarini License's second installment of development cost contributions, which was recorded in the previous year. For the first half of 2026, total revenue was $6.7 million, a 70% decrease compared to $22.1 million in the first half of 2025. The company also reported a net loss of $64.1 million for the quarter, compared to a loss of $17.4 million in the prior year, and a total loss of $112.6 million for the first half of 2026, up from $56.9 million in the same period last year.

Operating expenses increased to $68.6 million for the second quarter, up from $54.8 million in the previous year, driven by a 52% rise in research and development expenses, which reached $41.7 million. This increase was largely due to higher clinical trial costs and personnel expenses. Selling, general, and administrative expenses remained relatively stable, decreasing slightly to $26.9 million from $27.3 million. The company’s total operating loss for the quarter was $64.9 million, compared to a loss of $35.6 million in the same quarter of 2025.

In terms of strategic developments, NewAmsterdam Pharma has made significant progress in its clinical trials for obicetrapib, a treatment for lowering low-density lipoprotein cholesterol (LDL-C). The company has completed pivotal Phase 3 trials, including BROADWAY and BROOKLYN, which met their primary and secondary endpoints. The European Medicines Agency (EMA) has accepted marketing authorization applications for obicetrapib, and a positive opinion has been recommended for both the monotherapy and the fixed-dose combination with ezetimibe. If approved, these products could be launched in the fourth quarter of 2026.

As of June 30, 2026, NewAmsterdam Pharma had cash, cash equivalents, and marketable securities totaling $678.3 million, a decrease from $769.3 million at the end of 2025. The company’s employee headcount has also increased, reflecting its ongoing investment in research and development. The company continues to evaluate potential partnerships and acquisitions to enhance its product pipeline and market presence. Looking ahead, NewAmsterdam Pharma anticipates continued investment in clinical trials and regulatory processes, with expectations of significant losses as it seeks to bring obicetrapib to market.